| Date | Title | Description |
| 31.10.2024 | WuXi AppTec: A Beacon of Resilience in the Pharmaceutical Landscape | In the bustling world of pharmaceuticals, WuXi AppTec stands tall, a lighthouse guiding ships through turbulent waters. The company recently reported its financial results for the first three quarters of 2024, showcasing remarkable growth d... |
| 30.10.2024 | WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year | SHANGHAI, Oct. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Glo... |
| 28.10.2024 | Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-1... | Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year
Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-ove... |
| 11.09.2024 | The Rising Tide of Genomic Innovation: MGI's CycloneSEQ Technology and the Political Storm Surrounding Biotech | In the world of biotechnology, innovation is the lifeblood that fuels progress. MGI Tech Co., Ltd. has recently unveiled its latest advancements in nanopore sequencing technology, the CycloneSEQ-WT02 and CycloneSEQ-WY01. These products prom... |
| 07.09.2024 | Democrat to vote against bill restricting China's WuXi Biologics, BGI | Boards, Policy & RegulationHuman Rights
Democrat to vote against bill restricting China's WuXi Biologics, BGI
By Karen FreifeldSeptember 7, 20243:30 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Emai... |
| 31.07.2024 | WuXi AppTec: Navigating Challenges with Steady Growth in 2024 | In the turbulent waters of the pharmaceutical and life sciences industry, WuXi AppTec has managed to keep its ship afloat. The company’s recent financial results for the first half of 2024 reveal a narrative of resilience and strategic grow... |
| 29.07.2024 | Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ ... | Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year
Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year
Ne... |
| 29.07.2024 | Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ ... | Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year
Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year
Ne... |
| 15.05.2024 | Chinese biotech crackdown would reset U.S. drug development | figcaption>span]:font-sans">
Lawmakers in the House of Representatives on Wednesday are expected to set in motion a massive reordering of how U.S. pharmaceuticals are developed and made, by advancing a contracting ban on five key... |
| 29.04.2024 | WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations | Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8%
Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reached RMB0.66
Adjusted Non-IFRS Net Profit... |
| 18.03.2024 | WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time | Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6%
Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.... |
| 12.03.2024 | Drug Discovery Market Size, Share And Growth Analysis For 2024-2033 | Drug Discovery Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033
The Business Research Company’s Drug Discovery Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033
It will grow to $192.2 billion in ... |
| 06.03.2024 | US Senate Debates Bill Targeting Chinese Biotech Giants WuXi Apptec, BGI Over National Security Concerns | Quincy Jon, Tech Times 06 March 2024, 08:03 am
In a significant development on Capitol Hill, a groundbreaking bill in the U.S. Senate is poised for its inaugural examination in Congress on Wednesday.
This legislation, strategically crafted ... |
| 04.03.2024 | Pharmaceutical Manufacturing Market Projected to Grow at 7.8% CAGR, Reaching $863.6 Bn by 2030 | Vantage Market Research | Vantage Market Research
Pharmaceutical Manufacturing Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2030 WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- The Global Pharma... |
| 20.02.2024 | WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma | AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.
PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi A... |
| 30.10.2023 | WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth | Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to over RMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4%
Net Pro... |
| 31.07.2023 | WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022 | Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 39.5%
Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 2... |
| 24.04.2023 | WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022 | Revenue Up 5.8% Year-Over-Year to RMB8,964 Million
Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million
Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Year to RMB0.72
Adjusted Non-IFRS Net Profit... |
| 16.02.2023 | WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023 | SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver gro... |
| 21.12.2022 | WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index | SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow J... |
| 21.12.2022 | WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index | SHANGHAI, Dec. 21, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow J... |
| 26.10.2022 | WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion | Revenue Up 71.9% Year-Over-Year to RMB28,395 Million
Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million
Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30
Adjusted Non-IFRS Net Pro... |
| 14.10.2022 | Will the Taiwan Semiconductor Manufacturing Company of Drugs Be in East Asia? | On Aug. 25, President Biden signed the monumental $52.7 billion CHIPS and Science Act into law. The legislation is aimed to address the semiconductor manufacturing bottleneck in East Asia, namely the near-monopoly held on the industry by th... |
| 17.08.2022 | WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware | MIDDLETOWN, Del., Aug. 17, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus i... |
| 12.08.2022 | WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology | PHILADELPHIA, Aug. 12, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johns... |
| 19.07.2022 | WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation | SINGAPORE, July 19, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufactu... |
| 16.06.2022 | WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies | PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 16, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology co... |
| 25.04.2022 | WuXi AppTec Reports Record First-Quarter In 2022 | Revenue Up 71.2% Year-Over-Year to RMB8,474 Million
Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million
Diluted Earnings Per Share (EPS) Up 3.9% Year-Over-Year to RMB0.53
Adjusted Non-IFRS[1] Net Prof... |
| 08.04.2022 | WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics | SHANGHAI, April 8, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an ESG Risk Rating, recognizing it as a "Top ... |
| 09.12.2021 | WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan | SHANGHAI, Dec. 9, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Cus... |
| 29.10.2021 | WuXi AppTec Reports Strong Third-Quarter 2021 Results | WuXi AppTec Reports Strong Third-Quarter 2021 Results
2021/10/29
Revenue Up 30.6% Year-Over-Year to RMB5,985 Million
Net Profit Attributable to Owners of the Company Up 36.2% Year-Over-Year to RMB887 Million
Diluted EPS Up 30.4% Year-Over-Y... |
| 18.10.2021 | WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers | PHILADELPHIA, Oct. 18, 2021 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, S... |
| 06.09.2021 | WuXi AppTec Receives AA ESG Rating from MSCI | SHANGHAI, Sept. 6, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding ... |
| 06.09.2021 | WuXi AppTec : Receives AA ESG Rating from MSCI | SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding ... |
| 12.08.2021 | WuXi AppTec Reports Strong 2021 Interim Results | Revenue Up 45.7% Year-Over-Year to RMB10,537 Million
Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million
Diluted EPS Up 46.8% Year-Over-Year to RMB0.91
Adjusted Non-IFRS[1] Net Profit Attributable to... |
| 29.06.2021 | WuXi AppTec-backer Eight Roads launches $400m healthcare fund for China | Premium
Eight Roads, a global investment firm backed by US global financial services giant Fidelity Investments, on Tuesday announced the launch of its $400-million China-focused healthcare fund.
Continue reading this story with a subscript... |
| 29.06.2021 | WuXi AppTec-backer Eight Roads launches $400m healthcare fund for China | Eight Roads, a global investment firm backed by US global financial services giant Fidelity Investments, on Tuesday announced the launch of its $400-million China-focused healthcare fund.
Dubbed Eight Roads China Healthcare Fund V, the vehi... |
| 24.02.2021 | WuXi Diagnostics Secures US$150M in Series B Financing | WuXi Diagnostic Investment (Cayman) Limited, a Shangai, China-based diagnostics company, completed US$150m in series B funding.
Backers included new investors Thermo Fisher Scientific Inc., Shiyu Capital, ABC International Holdings Limited,... |
| 24.02.2021 | Chinese diagnostics firm WuXi Diagnostics raises $150m in Series B round | Premium
Chinese integrated diagnostics developer WuXi Diagnostics has raised $150 million in a Series B round of financing to advance its R&D pipeline and open-access innovation enabling platform, as the firm seeks to accelerate its mar... |
| 24.02.2021 | Chinese diagnostics firm WuXi Diagnostics raises $150m in Series B round | Chinese integrated diagnostics developer WuXi Diagnostics has raised $150 million in a Series B round of financing to advance its R&D pipeline and open-access innovation enabling platform, as the firm seeks to accelerate its market pene... |
| 18.11.2020 | Wuxi Biortus Biosciences Raises US$15M in Series A Financing | Wuxi Biortus Biosciences Co. Ltd., a Wuxi, China-based leader in structural biology service for drug discovery, closed a US$15m Series A financing.
The round was led by Bayland Capital.
The company intends to use the funds to establish a gl... |
| 19.02.2020 | General Atlantic, WuXi AppTec lead $98m Series D in CANbridge Pharma | Premium
CANbridge Pharmaceutical Inc that is focused on rare disease therapies has raised $98 million in its Series D round led by global private equity firm General Atlantic and existing investor WuXi AppTec, a Hong Kong and Shanghai dual-... |
| 10.12.2018 | WuXi AppTec starts a global wave of expansion, jumping off in San Diego following $1B Hong Kong IPO raise | As WuXi AppTec reportedly raises $1 billion from its public listing in Hong Kong donning a valuation of $10.2 billion, it’s beginning to check off some of the initiatives it has blueprinted.
The Chinese CRO giant has an... |
| 28.11.2018 | Chinese medical tech platform WuXi AppTec launches $1 billion HK listing | By Julia Fioretti
3 Min Read
HONG KONG (Reuters) - Shanghai-listed Chinese medical tech platform WuXi AppTec has launched a Hong Kong listing of up to $1.06 billion, braving weak markets and testing investor sentiment after a string of badl... |
| 28.11.2018 | Temasek-backed genomics firm Wuxi NextCODE raises $200m | Premium
WuXi NextCODE, the Temasek-backed Chinese genomics startup, has raised $200 million in a Series C financing round led by the Ireland Strategic Investment Fund (ISIF).
Continue reading this story with a subscription to DealStreetAsia... |
| 27.11.2018 | Global syndicate backs $400M genomics R&D play in Ireland as WuXi NextCODE extends its reach into Europe | The big push to translate fresh mounds of genomics data into new meds got a significant boost today as an international syndicate of investors from the US, China, Ireland and Singapore backed Wuxi NextCODE’s plan to add a... |
| 11.06.2018 | With strategic investment, Insilico Medicine is using deep learning to defeat aging | Every once in a while, you meet an entrepreneur who is both fully present, but also has a head full of dreams. That was my experience meeting and hosting Alex Zhavoronkov, the founder and CEO of Insilico Medicine, a few weeks ago in Vienna ... |
| 08.05.2018 | Listing in Shanghai, WuXi AppTec raises a $354M IPO for China R&D facilities | One day after Hong Kong’s stock exchange scored its first pre-revenue IPO application, Shanghai Stock Exchange got its own time in the limelight as global CRO WuXi AppTec hauled in $354 million (RMB2.3 billion) by going public... |
| 08.05.2018 | China Digest: Wuxi Vision nabs $12.6m from Qiming, Ruijian; Shenma fundraise | Premium
In the latest startup financing, Wuxi Vision Pro Ltd., an ophthalmic medical device maker, has secured RMB 80 million ($12.6 million) in a Series B round of financing from Qiming Venture Partners and Ruijian Capital. In another deve... |
| 07.05.2018 | Wuxi Vision raises $13M to commercialize cataract devices | Wuxi Vision Pro has raised $13 million to advance its intraocular lens business. The Chinese medical device company picked up a local approval for its products last year, setting it up to service the country’s growing number of cataract pat... |
| 28.03.2018 | Global CRO WuXi AppTec looks to raise $900M-plus from Shanghai IPO; Edge shares crushed on PhIII failure | → Ge Li’s WuXi AppTec has filed for an IPO in Shanghai that’s expected to haul in more than $900 million to back a new building program for their research and development facilities. The big CRO has extensive contacts throug... |
| 08.03.2018 | Juno, WuXi JV gets a $90M round as China’s CAR-T pioneers fly high with fresh cash | Hans Bishop
Close to two years after Hans Bishop at Juno and Ge Li at WuXi AppTec joined hands on a joint venture to create a CAR-T company in China, the biotech has rounded up a whopping $90 million round from a syndicate that... |
| 25.01.2018 | Fast-growing Shanghai Pharma to plant foot in San Diego, hunting deals in US and Europe | A multi-billion dollar Chinese pharma conglomerate, blessed with municipal government backing, is spreading its wings to the US and Europe with eyes on R&D, manufacturing and distribution.
The company, called S... |
| 07.09.2017 | Genomics firm WuXi NextCODE raises $240m from Sequoia China, Temasek, others | Premium
A Temasek-backed genomics firm has raised $240 million in its latest funding round from a consortium led by Sequoia Capital China, it said on Thursday, one of the largest such fundraisings in a hot area of scientific research.
Conti... |
| 03.05.2017 | Amgen backs WuXi NextCODE’s $75M B round; ImCheck bags €20 venture round for I-O work | → The global contract genomics outfit WuXi NextCODE raised a $75 million B round from an international consortium of investors. Amgen Ventures was involved, along with 3W Partners in a raise led by Temasek and Yunfeng Capi... |
| 15.12.2015 | WuXi Healthcare Ventures Closes $290M Fund | Chinese life sciences and healthcare venture capital firm WuXi Healthcare Ventures closed its $290m fund.
WuXi Healthcare Ventures II, L.P., which exceeded its initial target of $200m, builds on its predecessor fund launched in 2011, which ... |
| 18.11.2015 | Temasek, Hillhouse Capital invest $150m in Chinese home listings portal Aiwujiwu | Premium
Shangai-based Aiwujiwu, a Chinese rental and second-home listings portal, has completed a Series E round of funding worth $150 million round led by Singapore state fund Temasek Holdings and Hillhouse Capital.
Continue reading this s... |
| 14.07.2015 | WuXi launches $250M fund to invest in life sciences startups | We own 100% of this fund, to which we have made a capital funding commitment of up to $50 million, with an investment focus on technology and life-science companies. As of December 31, 2014, through this venture fund we had invested approxi... |
| 09.01.2014 | Avelas’ luminous mapping technology to guide breast cancer surgery attracts $6.85M | Avalon Ventures led the round and new investors Torrey Pines Investment, WuXi AppTec and an unnamed investor also took part.
One advantage of Avelas’ platform is that it can help surgeons evaluate tumor samples in real-time. According to th... |
| 13.08.2013 | WuXi Pharma Tech Raises Q3 Guidance; Jefferies Raise Price Target to $28 | Chinese contract research organization (CRO) WuXi Pharma Tech (WX) reported a strong Q2 and raised Q3 guidance, prompting Jefferies to raise their price target to $28 from $24. WX last traded at $23.76.
WX trades at a discount compared to i... |
| 24.08.2012 | Novira Therapeutics Secures $23M in Series A Financing | Novira Therapeutics Inc., a Radnor, PA-based antiviral drug discovery company, has secured $23m in Series A financing.
The round was co-led by new investors 5AM Ventures and Canaan Partners with participation from WuXi PharmaTech as well as... |
| 24.08.2012 | Novira Therapeutics raises $23M for hepatitis B treatment that attacks DNA of virus | Osvaldo (Lalo) Flores, the president and chief scientific officer of Novira Therapeutics in Radnor, Pennsylvania, told MedCity News in a phone interview that the biotechnology company’s capsid-targeting antivirals entering preclinical devel... |
| 26.04.2010 | Charles River Labs to pay $1.6 billion for WuXi PharmaTech | Charles River Laboratories International Inc. (NYSE:CRL) didn’t let disappointing first-quarter results slow it down, inking a $1.6 billion cash-and-stock deal to acquire Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX).
The Wincheste... |
| - | WuXi launches $250M fund to invest in life sciences startups | —The venture arm of China-based R&D powerhouse WuXi PharmaTech is raising its second venture fund, with aims to bring in $250 million, according to a new regulatory filing.
It plans to use the funding to invest in healthcare and life sc... |
| - | Avelas’ luminous mapping technology to guide breast cancer surgery attracts $6.85M | The development of ways to illuminate cancerous tissue to guide surgeons is a life science innovation that’s attracted a growing amount of interest. Avelas Biosciences has raised $6.85 million as part of a Series B round to advance its fluo... |
| - | Novira Therapeutics raises $23M for hepatitis B treatment that attacks DNA of virus | A biotechnology company with a novel drug treatment for hepatitis B and HIV patients could change the way drugs combat viruses. The drug, under development, which targets the outer shell, or capsids, of the viruses, has secured $23 million ... |
